{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:46:41Z","timestamp":1792176401805,"version":"4.4.0"},"reference-count":37,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9,1]]},"abstract":"<jats:p>OBJECTIVE. In utero exposure to drugs of abuse can lead to neonatal abstinence syndrome, a condition that is associated with prolonged hospitalization. Buprenorphine is a partial \u03bc-opioid agonist used for treatment of adult detoxification and maintenance but has never been administered to neonates with opioid abstinence syndrome. The primary objective of this study was to demonstrate the feasibility and, to the extent possible in this size of study, the safety of sublingual buprenorphine in the treatment of neonatal abstinence syndrome. Secondary goals were to evaluate efficacy relative to standard therapy and to characterize buprenorphine pharmacokinetics when sublingually administered.<\/jats:p>\n                  <jats:p>METHODS. We conducted a randomized, open-label, active-control study of sublingual buprenorphine for the treatment of opiate withdrawal. Thirteen term infants were allocated to receive sublingual buprenorphine 13.2 to 39.0 \u03bcg\/kg per day administered in 3 divided doses and 13 to receive standard-of-care oral neonatal opium solution. Dose decisions were made by using a modified Finnegan scoring system.<\/jats:p>\n                  <jats:p>RESULTS. Sublingual buprenorphine was largely effective in controlling neonatal abstinence syndrome. Greater than 98% of plasma concentrations ranged from undetectable to \u223c0.60 ng\/mL, which is less than needed to control abstinence symptoms in adults. The ratio of buprenorphine to norbuprenorphine was larger than that seen in adults, suggesting a relative impairment of N-dealkylation. Three infants who received buprenorphine and 1 infant who received standard of care reached protocol-specified maximum doses and required adjuvant therapy with phenobarbital. The mean length of treatment for those in the neonatal-opium-solution group was 32 compared with 22 days for the buprenorphine group. The mean length of stay for the neonatal-opium-solution group was 38 days compared with 27 days for those in the buprenorphine group. Treatment with buprenorphine was well tolerated.<\/jats:p>\n                  <jats:p>CONCLUSIONS. Buprenorphine administered via the sublingual route is feasible and apparently safe and may represent a novel treatment for neonatal abstinence syndrome.<\/jats:p>","DOI":"10.1542\/peds.2008-0571","type":"journal-article","created":{"date-parts":[[2008,8,11]],"date-time":"2008-08-11T20:25:00Z","timestamp":1218486300000},"page":"e601-e607","source":"Crossref","is-referenced-by-count":89,"title":["Sublingual Buprenorphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Trial"],"prefix":"10.1542","volume":"122","author":[{"given":"Walter K.","family":"Kraft","sequence":"first","affiliation":[{"name":"Departments of Pharmacology and Experimental Therapeutics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Gibson","sequence":"additional","affiliation":[{"name":"Pediatrics"},{"name":"A.I. DuPont Hospital for Children, Wilmington, Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Dysart","sequence":"additional","affiliation":[{"name":"Pediatrics"},{"name":"A.I. DuPont Hospital for Children, Wilmington, Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidula S.","family":"Damle","sequence":"additional","affiliation":[{"name":"Pediatrics"},{"name":"A.I. DuPont Hospital for Children, Wilmington, Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"LaRusso","sequence":"additional","affiliation":[{"name":"Departments of Pharmacology and Experimental Therapeutics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay S.","family":"Greenspan","sequence":"additional","affiliation":[{"name":"Pediatrics"},{"name":"A.I. DuPont Hospital for Children, Wilmington, Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Moody","sequence":"additional","affiliation":[{"name":"Center for Human Toxicology, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol","family":"Kaltenbach","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle E.","family":"Ehrlich","sequence":"additional","affiliation":[{"name":"Pediatrics"},{"name":"A.I. DuPont Hospital for Children, Wilmington, Delaware"},{"name":"Neurology, Jefferson Medical College, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2008,9,1]]},"reference":[{"key":"2021120905244234800_R1","doi-asserted-by":"crossref","unstructured":"Vega WA, Kolody B, Hwang J, Noble A. Prevalence and magnitude of perinatal substance exposures in California. N Engl J Med.\u20081993;16:329(12):850\u2013854","DOI":"10.1056\/NEJM199309163291207"},{"key":"2021120905244234800_R2","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics, Committee on Drugs. Neonatal drug withdrawal [published correction appears in Pediatrics. 1998;102(3 pt 1):660]. Pediatrics.\u20081998;101(6):1079\u20131088","DOI":"10.1542\/peds.101.6.1079"},{"key":"2021120905244234800_R3","doi-asserted-by":"crossref","unstructured":"Nandakumar N, Sankar VS. What is the best evidence based management of neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed.\u20082006;91(6):F463","DOI":"10.1136\/adc.2006.095166"},{"key":"2021120905244234800_R4","doi-asserted-by":"crossref","unstructured":"Sarkar S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol.\u20082006;1:26(1):15\u201317","DOI":"10.1038\/sj.jp.7211427"},{"key":"2021120905244234800_R5","doi-asserted-by":"crossref","unstructured":"Osborn DA, Jeffery HE, Cole M. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev.\u20082005;(3):CD002059","DOI":"10.1002\/14651858.CD002059.pub2"},{"key":"2021120905244234800_R6","doi-asserted-by":"crossref","unstructured":"Osborn DA, Jeffery HE, Cole MJ. Sedatives for opiate withdrawal in newborn infants. Cochrane Database Syst Rev.\u20082005;(3):CD002053","DOI":"10.1002\/14651858.CD002053.pub2"},{"key":"2021120905244234800_R7","doi-asserted-by":"crossref","unstructured":"Johnson K, Gerada C, Greenough A. Treatment of neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed.\u20082003;88(1):F2\u2013F5","DOI":"10.1136\/fn.88.1.F2"},{"key":"2021120905244234800_R8","doi-asserted-by":"crossref","unstructured":"Lainwala S, Brown ER, Weinschenk NP, Blackwell MT, Hagadorn JI. A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations. Adv Neonatal Care.\u20082005;5(5):265\u2013272","DOI":"10.1016\/j.adnc.2005.06.003"},{"key":"2021120905244234800_R9","doi-asserted-by":"crossref","unstructured":"Langenfeld S, Birkenfeld L, Herkenrath P, Muller C, Hellmich M, Theisohn M. Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug Alcohol Depend.\u20082005;77(1):31\u201336","DOI":"10.1016\/j.drugalcdep.2004.07.001"},{"key":"2021120905244234800_R10","doi-asserted-by":"crossref","unstructured":"Coyle MG, Ferguson A, Lagasse L, Oh W, Lester B. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr.\u20082002;140(5):561\u2013564","DOI":"10.1067\/mpd.2002.123099"},{"key":"2021120905244234800_R11","doi-asserted-by":"crossref","unstructured":"Jackson L, Ting A, McKay S, Galea P, Skeoch C. A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed.\u20082004;89(4):F300\u2013F304","DOI":"10.1136\/adc.2003.033555"},{"key":"2021120905244234800_R12","doi-asserted-by":"crossref","unstructured":"Krantz MJ, Mehler PS. Treating opioid dependence: growing implications for primary care. Arch Intern Med.\u20082004;164(3):277\u2013288","DOI":"10.1001\/archinte.164.3.277"},{"key":"2021120905244234800_R13","doi-asserted-by":"crossref","unstructured":"Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther.\u20081994;55(5):569\u2013580","DOI":"10.1038\/clpt.1994.71"},{"key":"2021120905244234800_R14","doi-asserted-by":"crossref","unstructured":"Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med.\u20082002;137(6):501\u2013504","DOI":"10.7326\/0003-4819-137-6-200209170-00010"},{"key":"2021120905244234800_R15","doi-asserted-by":"crossref","unstructured":"Greenwald M, Johanson CE, Bueller J, et al. Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry.\u20082007;61(1):101\u2013110","DOI":"10.1016\/j.biopsych.2006.04.043"},{"key":"2021120905244234800_R16","doi-asserted-by":"crossref","unstructured":"Michel E, Zernikow B. Buprenorphine in children: a clinical and pharmacological review [in German]. Schmerz.\u20082006;20(1):40\u201350","DOI":"10.1007\/s00482-005-0456-1"},{"key":"2021120905244234800_R17","doi-asserted-by":"crossref","unstructured":"Barrett DA, Simpson J, Rutter N, Kurihara-Bergstrom T, Shaw PN, Davis SS. The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates. Br J Clin Pharmacol.\u20081993;36(3):215\u2013219","DOI":"10.1111\/j.1365-2125.1993.tb04220.x"},{"key":"2021120905244234800_R18","doi-asserted-by":"crossref","unstructured":"Marquet P, Chevrel J, Lavignasse P, Merle L, Lachatre G. Buprenorphine withdrawal syndrome in a newborn. Clin Pharmacol Ther.\u20081997;62(5):569\u2013571","DOI":"10.1016\/S0009-9236(97)90053-9"},{"key":"2021120905244234800_R19","doi-asserted-by":"crossref","unstructured":"Maunuksela EL, Korpela R, Olkkola KT. Comparison of buprenorphine with morphine in the treatment of postoperative pain in children. Anesth Analg.\u20081988;67(3):233\u2013239","DOI":"10.1213\/00000539-198803000-00005"},{"key":"2021120905244234800_R20","unstructured":"Finnegan LP, Kaltenbach K. Neonatal abstinence syndrome. In: Hoekelman RA, Friedman SB, Nelson N, Seidel HM, eds. Primary Pediatric Care. 2nd ed. St Louis, MO: Mosby;1992:1367\u20131378"},{"key":"2021120905244234800_R21","doi-asserted-by":"crossref","unstructured":"Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend.\u20082005;79(1):1\u201310","DOI":"10.1016\/j.drugalcdep.2004.11.013"},{"key":"2021120905244234800_R22","doi-asserted-by":"crossref","unstructured":"Mamelle N, Cochet V, Claris O. Definition of fetal growth restriction according to constitutional growth potential. Biol Neonate.\u20082001;80(4):277\u2013285","DOI":"10.1159\/000047157"},{"key":"2021120905244234800_R23","doi-asserted-by":"crossref","unstructured":"Moody DE, Slawson MH, Strain EC, Laycock JD, Spanbauer AC, Foltz RL. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem.\u20082002;306(1):31\u201339","DOI":"10.1006\/abio.2002.5673"},{"key":"2021120905244234800_R24","doi-asserted-by":"crossref","unstructured":"Chang Y, Moody DE, McCance-Katz EF. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos.\u20082006;34(3):440\u2013448","DOI":"10.1124\/dmd.105.006148"},{"key":"2021120905244234800_R25","unstructured":"Mizrahi EM, Kellaway P. Diagnosis and Management of Neonatal Seizures. Philadelphia, PA: Lippincott-Raven;1998"},{"key":"2021120905244234800_R26","doi-asserted-by":"crossref","unstructured":"Jansson LM, Dipietro JA, Elko A, Velez M. Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. J Matern Fetal Neonatal Med.\u20082007;20(9):677\u2013685","DOI":"10.1080\/14767050701490327"},{"key":"2021120905244234800_R27","doi-asserted-by":"crossref","unstructured":"Kuhlman JJ Jr, Levine B, Johnson RE, Fudala PJ, Cone EJ. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction.\u20081998;93(4):549\u2013559","DOI":"10.1046\/j.1360-0443.1998.93454910.x"},{"key":"2021120905244234800_R28","doi-asserted-by":"crossref","unstructured":"Kart T, Christrup LL, Rasmussen M. Recommended use of morphine in neonates, infants and children based on a literature review: part 1\u2014pharmacokinetics. Paediatr Anaesth.\u20081997;7(1):5\u201311","DOI":"10.1046\/j.1460-9592.1997.d01-30.x"},{"key":"2021120905244234800_R29","doi-asserted-by":"crossref","unstructured":"Huang W, Moody DE, McCance-Katz EF. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. Ther Drug Monit.\u20082006;28(2):245\u2013251","DOI":"10.1097\/01.ftd.0000197094.92559.b4"},{"key":"2021120905244234800_R30","doi-asserted-by":"crossref","unstructured":"McGrath C, Buist A, Norman TR. Treatment of anxiety during pregnancy: effects of psychotropic drug treatment on the developing fetus. Drug Saf.\u20081999;20(2):171\u2013186","DOI":"10.2165\/00002018-199920020-00006"},{"key":"2021120905244234800_R31","doi-asserted-by":"crossref","unstructured":"Myllynen P, Vahakangas K. An examination of whether human placental perfusion allows accurate prediction of placental drug transport: studies with diazepam. J Pharmacol Toxicol Methods.\u20082002;48(3):131\u2013138","DOI":"10.1016\/S1056-8719(03)00038-8"},{"key":"2021120905244234800_R32","doi-asserted-by":"crossref","unstructured":"Wikner BN, Stiller CO, Kallen B, Asker C. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: maternal characteristics. Pharmacoepidemiol Drug Saf.\u20082007;16(9):988\u2013994","DOI":"10.1002\/pds.1391"},{"key":"2021120905244234800_R33","doi-asserted-by":"crossref","unstructured":"Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics.\u20082006;117(6). Available at: www.pediatrics.org\/cgi\/content\/full\/117\/6\/e1163","DOI":"10.1542\/peds.2005-1561"},{"key":"2021120905244234800_R34","doi-asserted-by":"crossref","unstructured":"Chambers CD, Polifka JE, Friedman JM. Drug safety in pregnant women and their babies: ignorance not bliss. Clin Pharmacol Ther.\u20082008;83(1):181\u2013183","DOI":"10.1038\/sj.clpt.6100448"},{"key":"2021120905244234800_R35","doi-asserted-by":"crossref","unstructured":"Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction.\u20082006;101(2):275\u2013281","DOI":"10.1111\/j.1360-0443.2006.01321.x"},{"key":"2021120905244234800_R36","doi-asserted-by":"crossref","unstructured":"Kahila H, Saisto T, Kivitie-Kallio S, Haukkamaa M, Halmesmaki E. A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome. Acta Obstet Gynecol Scand.\u20082007;86(2):185\u2013190","DOI":"10.1080\/00016340601110770"},{"key":"2021120905244234800_R37","doi-asserted-by":"crossref","unstructured":"Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend.\u20082003;21:70(2 suppl):S87\u2013S101","DOI":"10.1016\/S0376-8716(03)00062-0"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/122\/3\/e601\/1175680\/zpe0090800e601.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/122\/3\/e601\/1175680\/zpe0090800e601.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T10:33:12Z","timestamp":1684492392000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/122\/3\/e601\/72270\/Sublingual-Buprenorphine-for-Treatment-of-Neonatal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,1]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2008,9,1]]},"published-print":{"date-parts":[[2008,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2008-0571","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,1]]}}}